Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: The INSPECT experience (2008-2020).

Autor:	Bertino G; Department of Otolaryngology Head Neck Surgery, University of Pavia, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Foundation, Pavia, Italy., Groselj A; Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia., Campana LG; Department of Surgery, The Christie National Health Service (NHS) Foundation Trust, Manchester, United Kingdom., Kunte C; Department of Dermatosurgery and Dermatology, Artemed Fachklinik Munich, München, Germany., Schepler H; Department of Dermatology, University Medical Center, Johannes Gutenberg University, Mainz, Germany., Gehl J; Center for Experimental Drug and Gene Electrotransfer (CEDGE), Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Roskilde, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Muir T; Department of Reconstructive Plastic Surgery, James Cook University Hospital, Middlesbrough, United Kingdom., Clover JAP; Department of Plastic Surgery, Cork University Hospital, Cork, Ireland.; Cancer Research @UCC, University College Cork, Cork, Ireland., Quaglino P; Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy., Kis E; Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary., Mascherini M; Department of Surgical Sciences, Polyclinic Hospital San Martino, Genoa, Italy., Bisase B; Clinic for Head and Neck Cancer, Queen Victoria Hospital National Health Service (NHS) Foundation Trust, East Grinstead, United Kingdom., Pecorari G; Department of Surgical Sciences, Otolaryngology Clinic, University of Turin, Turin, Italy., Bechara F; Department of Dermatologic Surgery, Ruhr-University Bochum, Bochum, Germany., Matteucci P; Dept Plastic Surgery, Hull University Teaching Hospitals National Health Service (NHS) Trust, Hull, United Kingdom., Odili J; Department of Plastic Surgery, St. Georges University Hospitals National Health Service (NHS) Trust, London, United Kingdom., Russano F; Melanoma and Sarcoma Surgical Oncology Unit, Veneto Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy., Orlando A; Southmead Hospital, North Bristol National Health Service (NHS) Trust, Department of Plastic and Reconstructive Surgery, Bristol, United Kingdom., Pritchard-Jones R; Plastic Reconstructive Surgery, University of Liverpool, St. Helens & Knowsley Teaching Hospitals National Health Service (NHS) Trust, Liverpool, United Kingdom., Moir G; Department of Cutaneous Medicine and Surgery, The Royal London Hospital & Queen Mary University of London (QMUL), Bart's Health National Health Service (NHS) Trust, London, United Kingdom., Mowatt D; Department of Surgery, Christie Hospital, Manchester, United Kingdom., Silvestri B; Oncology and Haematology Unit, Azienda Unità Sanitaria Locale Socio Sanitaria (AULSS) 3 Serenissima-Mirano, Venice, Italy., Seccia V; Otorhinolaryngology Audiology and Phoniatric Unit, University Hospital of Pisa, Pisa, Italy., Saxinger W; Department of Dermatology, Klinikum Wels-Grieskirchen, Wels, Austria., de Terlizzi F; Department of Dermatology, Klinikum Wels-Grieskirchen, Wels, Austria., Sersa G; Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.; Faculty of Health Sciences, University of Ljubljana, Ljubljana, Slovenia.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2022 Sep 20; Vol. 12, pp. 951662. Date of Electronic Publication: 2022 Sep 20 (Print Publication: 2022).
DOI:	10.3389/fonc.2022.951662
Abstrakt:	Introduction: Cutaneous squamous cell carcinoma (cSCC) is a frequent skin cancer with a high risk of recurrence characterized by tumor infiltration and, in advanced cases, a poor prognosis. ECT (electrochemotherapy) is an alternative treatment option for locally advanced or recurrent cSCC that is unsuitable for surgical resection. In this study, we aimed to evaluate the data in the InspECT (International Network for Sharing Practice on ECT) registry of the referral centers and to clarify the indications for the use of ECT as a treatment modality for cSCC. Materials and Methods: Patients with primary, recurrent or locally advanced cSCC from 18 European centers were included. They underwent at least one ECT session with bleomycin between February 2008 and November 2020, which was performed following the European Standard Operating Procedures. Results: The analysis included 162 patients (mean age of 80 years; median, 1 lesion/patient). Side effects were mainly local and mild (hyperpigmentation, 11%; ulceration, 11%; suppuration, 4%). The response to treatment per patient was 62% complete and 21% partial. In the multivariate model, intravenous drug administration and small tumor size showed a significant association with a positive outcome (objective response). One-year local progression-free survival was significantly better (p<0.001) in patients with primary tumors (80% (95% C.I. 70%-90%) than in patients with locally advanced disease (49% (95% C.I. 30%-68%). Conclusion: In the present study, ECT showed antitumor activity and a favorable safety profile in patients with complex cSCC for whom there was no widely accepted standard of care. Better results were obtained in primary and small tumors (<3 cm) using intravenous bleomycin administration. Competing Interests: FT is an IGEA employer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Bertino, Groselj, Campana, Kunte, Schepler, Gehl, Muir, Clover, Quaglino, Kis, Mascherini, Bisase, Pecorari, Bechara, Matteucci, Odili, Russano, Orlando, Pritchard-Jones, Moir, Mowatt, Silvestri, Seccia, Saxinger, de Terlizzi and Sersa.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu